367514-87-2 Usage
Drug for the treatment of schizophrenia
Lurasidone is developed by Japan's Dainippon Sumitomo Pharma which is an atypical antipsychotic,and is a classification of drug registration 3.1 class, it is suitable for the treatment of patients with schizophrenia. Its efficacy is Determined in four six weeks in adult patients with schizophrenia controlled studies. The exact mechanism of the treatment of schizophrenia, like other atypical antipsychotics ,is not very clear,and may be related to the antagonism of the dopamine D2 and serotonin 2A (5-HT2A) receptors. For the treatment of schizophrenia, a study has reported lurasidone can improve cognitive function.
October 28, 2010 ,the FDA approved lurasidone hydrochloride (lurasidone HCI) tablets once a day for the first-line treatment of patients with schizophrenia, the trade name is Latuda.
Dosage: The recommended starting dose is 40 mg/d, the effective dose range is 40~120 mg /· d, the maximum recommended dose is 80 mg /· d. It should be taken with food.
Adverse reaction: common adverse reactions are somnolence, akathisia, nausea, Parkinson's disease-like symptoms and emotional anxiety. Lurasidone has no physical dependence, less likely to cause weight gain, it does not cause glucose, lipids (lipids), it changs the period between ECG and QT.
The above information is edited by the lookchem of Tian Ye.
Description
The atypical antipsychotic lurasidone (also known as SM-13496) was
approved in the United States in 2010 as an oral agent for the treatment
of patients with schizophrenia. Lurasidone has potent affinity for D2 (Ki= 1.7 nM)
and 5-HT2A (Ki= 2.0 nM) receptors and acts as an antagonist at both
receptors. It is also a partial agonist at the 5-HT1A receptor and,
unlike other atypical agents, is a potent antagonist at the 5-HT7 receptor;
both of these activities are thought to confer beneficial cognitive properties.
Lurasidone is further differentiated by its lack of affinity for muscarinic
and histamine H1 receptors and its weak affinity for the 5-HT2C
receptor. Antagonism at H1 and 5-HT2C receptors has been implicated in
weight gain associated with atypical agents, while muscarinic receptor
antagonism is associated with cognitive deficits.
Originator
Dainippon Sumitomo Pharma (Japan)
Definition
ChEBI: An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-m
thanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizoph
enia.
Brand name
Latuda
Check Digit Verification of cas no
The CAS Registry Mumber 367514-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,7,5,1 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 367514-87:
(8*3)+(7*6)+(6*7)+(5*5)+(4*1)+(3*4)+(2*8)+(1*7)=172
172 % 10 = 2
So 367514-87-2 is a valid CAS Registry Number.
InChI:InChI=1/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
367514-87-2Relevant articles and documents
Preparation method of lurasidone
-
Paragraph 0032-0046, (2021/07/31)
The invention relates to a preparation method of lurasidone. The preparation method comprises the following steps of: reacting a compound as shown in a formula (I) with a compound as shown in a formula (II) under the action of an organic solvent A and a catalyst A, and performing quenching with a weak base solution to obtain a lurasidone crude product. According to the preparation method, the organic solvent A is selected from N-methyl pyrrolidone, N, N-dimethylformamide or a mixture of N-methyl pyrrolidone and N, N-dimethylformamide, preferably N-methyl pyrrolidone; the catalyst A is cesium carbonate; the weak base solution is selected from a cesium carbonate solution, a potassium carbonate solution or a sodium carbonate solution, preferably the potassium carbonate solution. The method is simple to operate, high in product yield, short in reaction time, low in cost and suitable for actual industrial production.
Preparation of west lulalula alkone isomer impurities (by machine translation)
-
Paragraph 0016, (2019/04/26)
West hydrochloric acid lulalula alkone, chemical name: (3 aR, 4S, 7R, 7 AS) - 2 - {(1R, 2R) - 2 - [4 - (1, 2 - Benzothiazole - 3 - yl) piperazine - 1 - yl methyl] cyclohexyl methyl} hexahydro - 1H- 4, 7 - Methyl isobutyl ketone indole - 1, 3 - dione hydro
Preparation method for lurasidone hydrochloride
-
, (2017/08/30)
The invention discloses a preparation method for lurasidone hydrochloride. According to the preparation method, trans-1,2-cyclohexanedicarboxylic acid (SM-1) is used as a raw material and subjected to resolution, methyl esterification, reduction, methylsulfonylation, condensation, recrystallization and salt formation so as to eventually obtain lurasidone hydrochloride. The preparation method provided by the invention greatly reduces production cost and has the characteristics of high product yield, easy operation, low toxicity and suitability for industrial large-scale production.